{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T20:09:51Z","timestamp":1762459791680,"version":"build-2065373602"},"reference-count":45,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,11,5]],"date-time":"2019-11-05T00:00:00Z","timestamp":1572912000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1016\/j.vaccine.2019.10.096","type":"journal-article","created":{"date-parts":[[2019,11,11]],"date-time":"2019-11-11T09:06:16Z","timestamp":1573463176000},"page":"2077-2087","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Proteomic profiling of precipitated Clostridioides difficile toxin A and B antibodies"],"prefix":"10.1016","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0539-550X","authenticated-orcid":false,"given":"Penelope J.","family":"Adamson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing J.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natalie G.","family":"Anosova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alex D.","family":"Colella","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Timothy K.","family":"Chataway","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harry","family":"Kleanthous","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tom P.","family":"Gordon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David L.","family":"Gordon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2019.10.096_b0005","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.anaerobe.2016.06.008","article-title":"Reclassification of Clostridium difficile as Clostridioides difficile (Hall and O'Toole 1935) Pr\u00e9vot 1938","volume":"40","author":"Lawson","year":"2016","journal-title":"Anaerobe"},{"key":"10.1016\/j.vaccine.2019.10.096_b0010","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1038\/nrgastro.2016.25","article-title":"Clostridium difficile Infection: Epidemiology, Diagnosis and Understanding Transmission","volume":"13","author":"Martin","year":"2016","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.vaccine.2019.10.096_b0015","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1016\/0016-5085(78)90457-2","article-title":"Role of Clostridium difficile in antibiotic-associated pseudomembranous colitis","volume":"75","author":"Bartlett","year":"1978","journal-title":"Gastroenterology"},{"key":"10.1016\/j.vaccine.2019.10.096_b0020","doi-asserted-by":"crossref","first-page":"e0167101","DOI":"10.1371\/journal.pone.0167101","article-title":"Highly Divergent Clostridium difficile strains isolated from the environment","volume":"11","author":"Janezic","year":"2016","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2019.10.096_b0025","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/s40121-016-0117-y","article-title":"Epidemiology and risk factors for community-associated Clostridium difficile Infection: a narrative review","volume":"5","author":"Bloomfield","year":"2016","journal-title":"Infect Dis and Ther."},{"key":"10.1016\/j.vaccine.2019.10.096_b0030","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1093\/infdis\/136.5.701","article-title":"Clindamycin-associated colitis due to a toxin-producing species of Clostridium in hamsters","volume":"136","author":"Bartlett","year":"1977","journal-title":"J Infect Dis."},{"key":"10.1016\/j.vaccine.2019.10.096_b0035","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1086\/383045","article-title":"Secular trends in hospital-acquired Clostridium difficile disease in the United States, 1987\u20132001","volume":"189","author":"Archibald","year":"2004","journal-title":"J Infect Dis."},{"key":"10.1016\/j.vaccine.2019.10.096_b0040","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1128\/CMR.00082-09","article-title":"The changing epidemiology of Clostridium difficile infections","volume":"23","author":"Freeman","year":"2010","journal-title":"Clin Microbiol Rev."},{"key":"10.1016\/j.vaccine.2019.10.096_b0045","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.surg.2017.01.018","article-title":"Clostridium difficile disease: diagnosis, pathogenesis, and treatment update","volume":"162","author":"Napolitano","year":"2017","journal-title":"Surgery"},{"key":"10.1016\/j.vaccine.2019.10.096_b0050","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.anaerobe.2013.05.005","article-title":"A clinical and epidemiological review of non-toxigenic Clostridium difficile","volume":"22","author":"Natarajan","year":"2013","journal-title":"Anaerobe"},{"key":"10.1016\/j.vaccine.2019.10.096_b0055","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1146\/annurev-micro-090816-093458","article-title":"Clostridium difficile toxin biology","volume":"71","author":"Aktories","year":"2017","journal-title":"Annu Rev Microbiol."},{"key":"10.1016\/j.vaccine.2019.10.096_b0060","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.00551-15","article-title":"Defining the roles of TcdA and TcdB in localized gastrointestinal disease, systemic organ damage, and the host response during Clostridium difficile Infections","volume":"6","author":"Carter","year":"2015","journal-title":"mBio"},{"key":"10.1016\/j.vaccine.2019.10.096_b0065","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1038\/nature07822","article-title":"Toxin B is essential for Virulence of Clostridium difficile","volume":"458","author":"Lyras","year":"2009","journal-title":"Nature"},{"key":"10.1016\/j.vaccine.2019.10.096_b0070","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1038\/nature09397","article-title":"The Role of Toxin A and Toxin B in Clostridium difficile Infection","volume":"467","author":"Kuehne","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.vaccine.2019.10.096_b0075","doi-asserted-by":"crossref","first-page":"121","DOI":"10.4161\/gmic.19399","article-title":"Clostridium difficile infection: toxins and non-toxin virulence factors, and their contributions to disease establishment and host response","volume":"3","author":"Vedantam","year":"2012","journal-title":"Gut Microbes"},{"key":"10.1016\/j.vaccine.2019.10.096_b0080","doi-asserted-by":"crossref","first-page":"209","DOI":"10.2147\/CEG.S84017","article-title":"An update on antibody-based immunotherapies for Clostridium difficile infection","volume":"9","author":"Hussack","year":"2016","journal-title":"Clin Exp Gastroenterol"},{"key":"10.1016\/j.vaccine.2019.10.096_b0085","doi-asserted-by":"crossref","first-page":"998","DOI":"10.3390\/toxins2050998","article-title":"Toxin-specific antibodies for the treatment of Clostridium difficile: current status and future perspectives","volume":"2","author":"Hussack","year":"2010","journal-title":"Toxins"},{"key":"10.1016\/j.vaccine.2019.10.096_b0090","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1128\/CVI.00116-14","article-title":"Antibodies for treatment of Clostridium difficile infection","volume":"21","author":"Humphreys","year":"2014","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.vaccine.2019.10.096_b0095","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1056\/NEJMoa1602615","article-title":"Bezlotoxumab for prevention of recurrent Clostridium difficile infection","volume":"376","author":"Wilcox","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2019.10.096_b0100","doi-asserted-by":"crossref","first-page":"397","DOI":"10.14740\/gr1091","article-title":"Long-term safety and efficacy of fecal microbiota transplantation in the treatment of Clostridium difficile infection in patients with and without inflammatory bowel disease: a tertiary care center's experience","volume":"11","author":"Tabbaa","year":"2018","journal-title":"Gastroenterol Res"},{"key":"10.1016\/j.vaccine.2019.10.096_b0105","doi-asserted-by":"crossref","first-page":"4307","DOI":"10.1016\/j.vaccine.2012.01.056","article-title":"Clostridium difficile: development of a novel candidate vaccine","volume":"30","author":"Foglia","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.10.096_b0110","doi-asserted-by":"crossref","first-page":"2245","DOI":"10.1016\/j.vaccine.2012.01.065","article-title":"Phase I dose finding studies of an adjuvanted Clostridium difficile toxoid vaccine","volume":"30","author":"Greenberg","year":"2012","journal-title":"Vaccine."},{"key":"10.1016\/j.vaccine.2019.10.096_b0115","doi-asserted-by":"crossref","first-page":"2170","DOI":"10.1016\/j.vaccine.2016.03.028","article-title":"Defining the optimal formulation and schedule of a candidate toxoid vaccine against Clostridium difficile infection: a randomized phase 2 clinical trial","volume":"34","author":"de Bruyn","year":"2016","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.10.096_b0120","doi-asserted-by":"crossref","first-page":"2082","DOI":"10.1016\/j.vaccine.2016.03.010","article-title":"A phase 1, placebo-controlled, randomized study of the safety, tolerability, and Immunogenicity of a Clostridium difficile vaccine administered with or without aluminum hydroxide in healthy adults","volume":"34","author":"Sheldon","year":"2016","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.10.096_b0125","doi-asserted-by":"crossref","first-page":"2585","DOI":"10.1016\/j.vaccine.2016.03.098","article-title":"Safety, immunogenicity and dose response of VLA84, a new vaccine candidate against Clostridium difficile, in healthy volunteers","volume":"34","author":"Bezay","year":"2016","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.10.096_b0130","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0074452","article-title":"Circulating antibody and memory B-cell responses to C. difficile toxins A and B in patients with C. difficile-associated diarrhoea, inflammatory bowel disease and cystic fibrosis","volume":"8","author":"Monaghan","year":"2013","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2019.10.096_b0135","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1128\/CVI.00190-15","article-title":"Profiling humoral immune responses to Clostridium difficile-specific antigens by protein microarray analysis","volume":"22","author":"Negm","year":"2015","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.vaccine.2019.10.096_b0140","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1128\/CVI.00763-14","article-title":"A Combination of three fully human toxin A- and toxin B-specific monoclonal antibodies protects against challenge with highly virulent epidemic strains of Clostridium difficile in the hamster model","volume":"22","author":"Anosova","year":"2015","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.vaccine.2019.10.096_b0145","doi-asserted-by":"crossref","first-page":"5576","DOI":"10.1016\/j.vaccine.2017.08.053","article-title":"Proteomic analysis of influenza haemagglutinin-specific antibodies following vaccination reveals convergent immunoglobulin variable region signatures","volume":"35","author":"Adamson","year":"2017","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.10.096_b0150","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1111\/cei.13197","article-title":"Precipitating anti-dsDNA peptide repertoires in lupus","volume":"194","author":"Wang","year":"2018","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.vaccine.2019.10.096_b0155","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1002\/art.40539","article-title":"Molecular profiling and clonal tracking of secreted rheumatoid factors in primary Sj\u00f6gren's syndrome","volume":"70","author":"Wang","year":"2018","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.vaccine.2019.10.096_b0160","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.autrev.2016.01.008","article-title":"Secreted autoantibody repertoires in Sj\u00f6gren's syndrome and systemic lupus erythematosus: a proteomic approach","volume":"15","author":"Al Kindi","year":"2016","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.vaccine.2019.10.096_b0165","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.clim.2016.09.001","article-title":"IgV peptide mapping of native Ro60 autoantibody proteomes in primary Sj\u00f6gren's syndrome reveals molecular markers of Ro\/La diversification","volume":"173","author":"Wang","year":"2016","journal-title":"Clin Immunol"},{"key":"10.1016\/j.vaccine.2019.10.096_b0170","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.jaut.2014.12.005","article-title":"Serum SmD autoantibody proteomes are clonally restricted and share variable-region peptides","volume":"57","author":"Al Kindi","year":"2015","journal-title":"J Autoimmun"},{"key":"10.1016\/j.vaccine.2019.10.096_b0175","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1111\/cei.12750","article-title":"Lupus anti-ribosomal P autoantibody proteomes express convergent biclonal signatures","volume":"184","author":"Al Kindi","year":"2016","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.vaccine.2019.10.096_b0180","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0022365","article-title":"High-resolution description of antibody heavy-chain repertoires in humans","volume":"6","author":"Arnaout","year":"2011","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2019.10.096_b0185","doi-asserted-by":"crossref","first-page":"18008","DOI":"10.1074\/jbc.M114.560748","article-title":"Mechanism of action and epitopes of Clostridium difficile toxin B-neutralizing antibody Bezlotoxumab revealed by X-ray crystallography","volume":"289","author":"Orth","year":"2014","journal-title":"J Biol Chem"},{"key":"10.1016\/j.vaccine.2019.10.096_b0190","doi-asserted-by":"crossref","first-page":"6339","DOI":"10.1128\/IAI.00982-06","article-title":"Human monoclonal antibodies directed against toxins A and B prevent Clostridium difficile-induced mortality in hamsters","volume":"74","author":"Babcock","year":"2006","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2019.10.096_b0195","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1038\/nm.4224","article-title":"Molecular-level analysis of the serum antibody repertoire in young adults before and after seasonal influenza vaccination","volume":"22","author":"Lee","year":"2016","journal-title":"Nat Med"},{"key":"10.1016\/j.vaccine.2019.10.096_b0200","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1056\/NEJM200002103420604","article-title":"Asymptomatic carriage of Clostridium difficile and serum levels of IgG antibody against toxin A","volume":"342","author":"Kyne","year":"2000","journal-title":"N Engl J Med."},{"key":"10.1016\/j.vaccine.2019.10.096_b0205","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/S0140-6736(00)03592-3","article-title":"Association Between antibody response to toxin A and protection against recurrent Clostridium difficile diarrhoea","volume":"357","author":"Kyne","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2019.10.096_b0210","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/BF01642866","article-title":"Serum antibody response to Clostridium difficile toxins in patients with Clostridium difficile diarrhoea","volume":"13","author":"Aronsson","year":"1985","journal-title":"Infection"},{"key":"10.1016\/j.vaccine.2019.10.096_b0215","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1128\/iai.62.2.384-389.1994","article-title":"Human antibody response to Clostridium difficile toxin A in relation to clinical course of infection","volume":"62","author":"Warny","year":"1994","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2019.10.096_b0220","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1016\/j.vaccine.2009.10.144","article-title":"Serum anti-toxin B antibody correlates with protection from recurrent Clostridium difficile infection (CDI)","volume":"28","author":"Leav","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.10.096_b0225","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1099\/jmm.0.030015-0","article-title":"The host immune response to Clostridium difficile","volume":"60","author":"Kelly","year":"2011","journal-title":"J Med Microbiol"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X19314963?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X19314963?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T10:41:14Z","timestamp":1759401674000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X19314963"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2]]},"references-count":45,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2020,2]]}},"alternative-id":["S0264410X19314963"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2019.10.096","relation":{},"ISSN":["0264-410X"],"issn-type":[{"type":"print","value":"0264-410X"}],"subject":[],"published":{"date-parts":[[2020,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Proteomic profiling of precipitated Clostridioides difficile toxin A and B antibodies","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2019.10.096","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}